Samil Pharmaceutical Co.,Ltd (000520.KS)
KRW 13130.0
(-3.95%)
KRW 13130.0
(-3.95%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 6.47 Billion KRW | 60.83% |
| 2022 | 4.01 Billion KRW | 280.78% |
| 2021 | 1.05 Billion KRW | -83.87% |
| 2020 | 6.53 Billion KRW | 35.57% |
| 2019 | 4.82 Billion KRW | 184.14% |
| 2018 | -5.73 Billion KRW | -538.54% |
| 2017 | 1.3 Billion KRW | -66.08% |
| 2016 | 3.85 Billion KRW | 140.47% |
| 2015 | 1.6 Billion KRW | 118.6% |
| 2014 | -8.61 Billion KRW | -335.42% |
| 2013 | -1.97 Billion KRW | -25.61% |
| 2012 | -1.57 Billion KRW | 77.37% |
| 2011 | -6.95 Billion KRW | -1365.41% |
| 2010 | 549.99 Million KRW | 104.95% |
| 2009 | -11.12 Billion KRW | -254.03% |
| 2008 | 7.22 Billion KRW | -33.32% |
| 2007 | 10.82 Billion KRW | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 1.09 Billion KRW | -46.78% |
| 2024 Q1 | 2.07 Billion KRW | -4.38% |
| 2023 FY | 6.46 Billion KRW | 60.83% |
| 2023 Q4 | 2.16 Billion KRW | 134.38% |
| 2023 Q2 | 1.8 Billion KRW | 15.27% |
| 2023 Q1 | 1.56 Billion KRW | 218.04% |
| 2023 Q3 | 925.55 Million KRW | -48.64% |
| 2022 Q4 | -1.32 Billion KRW | -290.32% |
| 2022 FY | 4.01 Billion KRW | 280.78% |
| 2022 Q2 | 2.29 Billion KRW | -2.12% |
| 2022 Q3 | 695.98 Million KRW | -69.71% |
| 2022 Q1 | 2.34 Billion KRW | 249.96% |
| 2021 Q2 | 171.28 Million KRW | -89.13% |
| 2021 Q3 | 217.59 Million KRW | 27.03% |
| 2021 Q1 | 1.57 Billion KRW | 2996.21% |
| 2021 FY | 1.05 Billion KRW | -83.87% |
| 2021 Q4 | -1.56 Billion KRW | -819.41% |
| 2020 Q3 | 1.04 Billion KRW | -51.02% |
| 2020 FY | 6.53 Billion KRW | 35.57% |
| 2020 Q1 | 3.3 Billion KRW | 220.98% |
| 2020 Q2 | 2.13 Billion KRW | -35.44% |
| 2020 Q4 | 50.9 Million KRW | -95.13% |
| 2019 Q3 | 166.18 Million KRW | -85.06% |
| 2019 Q4 | 1.03 Billion KRW | 519.91% |
| 2019 Q2 | 1.11 Billion KRW | -55.74% |
| 2019 Q1 | 2.51 Billion KRW | 227.99% |
| 2019 FY | 4.82 Billion KRW | 184.14% |
| 2018 Q3 | -2 Billion KRW | -77.85% |
| 2018 FY | -5.73 Billion KRW | -538.54% |
| 2018 Q4 | -1.96 Billion KRW | 1.89% |
| 2018 Q2 | -1.12 Billion KRW | -75.76% |
| 2018 Q1 | -640.39 Million KRW | -165.47% |
| 2017 FY | 1.3 Billion KRW | -66.08% |
| 2017 Q3 | -1.65 Billion KRW | -381.03% |
| 2017 Q4 | 978.12 Million KRW | 159.18% |
| 2017 Q2 | 588.12 Million KRW | -57.8% |
| 2017 Q1 | 1.39 Billion KRW | -20.05% |
| 2016 Q1 | 900.61 Million KRW | 238.12% |
| 2016 Q4 | 1.74 Billion KRW | 177.32% |
| 2016 FY | 3.85 Billion KRW | 140.47% |
| 2016 Q3 | 628.5 Million KRW | 8.14% |
| 2016 Q2 | 581.2 Million KRW | -35.47% |
| 2015 Q1 | 1.09 Billion KRW | 135.02% |
| 2015 Q4 | 266.36 Million KRW | -36.95% |
| 2015 Q3 | 422.42 Million KRW | 328.14% |
| 2015 Q2 | -185.16 Million KRW | -116.85% |
| 2015 FY | 1.6 Billion KRW | 118.6% |
| 2014 Q3 | -2.72 Billion KRW | -14.12% |
| 2014 Q4 | -3.13 Billion KRW | -15.16% |
| 2014 FY | -8.61 Billion KRW | -335.42% |
| 2014 Q1 | -364.95 Million KRW | 78.07% |
| 2014 Q2 | -2.38 Billion KRW | -554.28% |
| 2013 Q4 | -1.66 Billion KRW | -164.2% |
| 2013 Q1 | 122.58 Million KRW | 119.24% |
| 2013 Q2 | 193.16 Million KRW | 57.58% |
| 2013 FY | -1.97 Billion KRW | -25.61% |
| 2013 Q3 | -629.99 Million KRW | -426.13% |
| 2012 Q3 | -282.41 Million KRW | -196.48% |
| 2012 Q4 | -637.07 Million KRW | -125.58% |
| 2012 FY | -1.57 Billion KRW | 77.37% |
| 2012 Q1 | -687.23 Million KRW | 0.0% |
| 2012 Q2 | 292.7 Million KRW | 142.59% |
| 2011 Q4 | - KRW | 100.0% |
| 2011 FY | -6.95 Billion KRW | -1365.41% |
| 2011 Q3 | -779.3 Million KRW | 31.96% |
| 2011 Q2 | -1.14 Billion KRW | -265.74% |
| 2011 Q1 | -313.17 Million KRW | -121.37% |
| 2010 FY | 549.99 Million KRW | 104.95% |
| 2010 Q3 | -1.21 Billion KRW | -530.03% |
| 2010 Q4 | 1.46 Billion KRW | 220.34% |
| 2010 Q2 | 283.13 Million KRW | 1376.84% |
| 2010 Q1 | 19.17 Million KRW | 100.7% |
| 2009 Q4 | -2.75 Billion KRW | -1.51% |
| 2009 Q1 | -1.8 Billion KRW | 52.98% |
| 2009 Q3 | -2.71 Billion KRW | 29.21% |
| 2009 Q2 | -3.83 Billion KRW | -112.13% |
| 2009 FY | -11.12 Billion KRW | -254.03% |
| 2008 Q1 | 5.6 Billion KRW | 317.18% |
| 2008 Q3 | 915.08 Million KRW | -79.88% |
| 2008 FY | 7.22 Billion KRW | -33.32% |
| 2008 Q2 | 4.54 Billion KRW | -18.88% |
| 2008 Q4 | -3.84 Billion KRW | -520.46% |
| 2007 Q1 | 5.33 Billion KRW | 0.0% |
| 2007 Q2 | 4.68 Billion KRW | -12.22% |
| 2007 Q3 | 2.81 Billion KRW | -39.83% |
| 2007 FY | 10.82 Billion KRW | 0.0% |
| 2007 Q4 | -2.58 Billion KRW | -191.58% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 364.53 Million KRW | -1675.136% |
| Dong-A Socio Holdings Co., Ltd. | 76.88 Billion KRW | 91.583% |
| Ildong Holdings Co., Ltd. | -79.56 Billion KRW | 108.133% |
| HANDOK Inc. | 12.57 Billion KRW | 48.556% |
| Kukje Pharma Co., Ltd. | -1.98 Billion KRW | 425.317% |
| Yuhan Corporation | 74.56 Billion KRW | 91.321% |
| Dong-A ST Co., Ltd. | 11.17 Billion KRW | 42.112% |
| SAMSUNG PHARM. Co., LTD. | -18.04 Billion KRW | 135.865% |
| Hanmi Pharm. Co., Ltd. | 224.88 Billion KRW | 97.123% |
| Hanall Biopharma Co.,Ltd | 3.05 Billion KRW | -111.744% |
| Ilyang Pharmaceutical Co.,Ltd | 14.35 Billion KRW | 54.907% |
| Dong Sung Bio Pharm.Co.,Ltd. | 596.4 Million KRW | -985.01% |
| MYUNGMOON Pharm co.,Ltd | 963.76 Million KRW | -571.432% |
| Hana Pharm Co., Ltd. | 27.03 Billion KRW | 76.061% |
| Yuyu Pharma, Inc. | 364.53 Million KRW | -1675.136% |
| Ilsung Pharmaceuticals Co., Ltd. | -7.75 Billion KRW | 183.432% |
| REYON Pharmaceutical Co., Ltd. | 4.03 Billion KRW | -60.427% |
| Aprogen pharmaceuticals,Inc. | -69.95 Billion KRW | 109.251% |
| JW Holdings Corporation | 143.66 Billion KRW | 95.496% |
| Ildong Pharmaceutical Co., Ltd. | -53.41 Billion KRW | 112.114% |
| Chong Kun Dang Pharmaceutical Corp. | 246.59 Billion KRW | 97.376% |
| JW Pharmaceutical Corporation | 100.3 Billion KRW | 93.549% |
| Shin Poong Pharm.Co.,Ltd. | -47.39 Billion KRW | 113.654% |
| Hyundai Pharmaceutical Co., Ltd. | 6.92 Billion KRW | 6.582% |
| Jeil Pharmaceutical Co.,Ltd | 8.73 Billion KRW | 25.888% |
| Yuyu Pharma, Inc. | 364.53 Million KRW | -1675.136% |
| Kwang Dong Pharmaceutical Co., Ltd. | 48.76 Billion KRW | 86.731% |
| Daewoong pharmaceutical Co.,Ltd | 133.4 Billion KRW | 95.149% |
| JW Pharmaceutical Corporation | 100.3 Billion KRW | 93.549% |
| Yuhan Corporation | 74.56 Billion KRW | 91.321% |
| Jeil Pharma Holdings Inc | 20.92 Billion KRW | 69.068% |
| Yungjin Pharm. Co., Ltd. | 3.11 Billion KRW | -107.578% |
| Suheung Co., Ltd. | 42.99 Billion KRW | 84.949% |
| JW Pharmaceutical Corporation | 100.3 Billion KRW | 93.549% |
| Samjin Pharmaceuticals Co., Ltd. | 20.48 Billion KRW | 68.41% |
| Korea United Pharm Inc. | 54.94 Billion KRW | 88.224% |
| CKD Bio Corp. | -20.15 Billion KRW | 132.11% |
| Daewon Pharmaceutical Co., Ltd. | 32.23 Billion KRW | 79.924% |
| Dongwha Pharm.Co.,Ltd | 25.3 Billion KRW | 74.425% |
| Whan In Pharm Co.,Ltd. | 32.52 Billion KRW | 80.105% |
| Shin Poong Pharm.Co.,Ltd. | -47.39 Billion KRW | 113.654% |
| Chong Kun Dang Holdings Corp. | 33.14 Billion KRW | 80.478% |
| Boryung Corporation | 68.26 Billion KRW | 90.521% |
| Bukwang Pharmaceutical Co., Ltd. | -37.49 Billion KRW | 117.258% |
| Ilyang Pharmaceutical Co.,Ltd | 14.35 Billion KRW | 54.907% |
| JW Lifescience Corporation | 32.09 Billion KRW | 79.836% |